Literature DB >> 10675330

C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B.

C L Smith-Hicks1, K C Sizer, J F Powers, A S Tischler, F Costantini.   

Abstract

Dominantly inherited multiple endocrine neoplasia type 2B (MEN2B) is characterized by tumors of the thyroid C-cells and adrenal chromaffin cells, together with ganglioneuromas of the gastrointestinal tract and other developmental abnormalities. Most cases are caused by substitution of threonine for Met918 in the RET receptor tyrosine kinase, which is believed to convert the RET gene to an oncogene by altering the enzyme's substrate specificity. We report the production of a mouse model of MEN2B by introduction of the corresponding mutation into the ret gene. Mutant mice displayed C-cell hyperplasia and chromaffin cell hyperplasia progressing to pheochromocytoma. Homozygotes did not develop gastrointestinal ganglioneuromas, but displayed ganglioneuromas of the adrenal medulla, enlargement of the associated sympathetic ganglia and a male reproductive defect. Surprisingly, homozygotes did not display any developmental defects attributable to a loss-of-function mutation. Thus, while our results support the conclusion that the Met918Thr substitution is responsible for MEN2B, they suggest that the substrate specificity of the RET kinase does not interfere with its normal role in the development of the kidneys and enteric nervous system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10675330      PMCID: PMC305599          DOI: 10.1093/emboj/19.4.612

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  53 in total

Review 1.  GDNF family neurotrophic factor signaling: four masters, one servant?

Authors:  M S Airaksinen; A Titievsky; M Saarma
Journal:  Mol Cell Neurosci       Date:  1999-05       Impact factor: 4.314

2.  A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry.

Authors:  S R Shi; C Coté; K L Kalra; C R Taylor; A K Tandon
Journal:  J Histochem Cytochem       Date:  1992-06       Impact factor: 2.479

Review 3.  The MEN II syndromes and the role of the ret proto-oncogene.

Authors:  B A Ponder; D Smith
Journal:  Adv Cancer Res       Date:  1996       Impact factor: 6.242

Review 4.  RET in human development and oncogenesis.

Authors:  P Edery; C Eng; A Munnich; S Lyonnet
Journal:  Bioessays       Date:  1997-05       Impact factor: 4.345

5.  Germline mutation of RET codon 883 in two cases of de novo MEN 2B.

Authors:  D P Smith; C Houghton; B A Ponder
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

6.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

Review 7.  Multiple endocrine neoplasia, type 2b.

Authors:  J A Carney; G W Sizemore; A B Hayles
Journal:  Pathobiol Annu       Date:  1978

8.  Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.

Authors:  N Asai; T Iwashita; M Matsuyama; M Takahashi
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

9.  Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret.

Authors:  A Schuchardt; V D'Agati; L Larsson-Blomberg; F Costantini; V Pachnis
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962

10.  Renal agenesis and hypodysplasia in ret-k- mutant mice result from defects in ureteric bud development.

Authors:  A Schuchardt; V D'Agati; V Pachnis; F Costantini
Journal:  Development       Date:  1996-06       Impact factor: 6.868

View more
  33 in total

Review 1.  Medullary thyroid cancer: monitoring and therapy.

Authors:  Douglas W Ball
Journal:  Endocrinol Metab Clin North Am       Date:  2007-09       Impact factor: 4.741

2.  A Drosophila model of multiple endocrine neoplasia type 2.

Authors:  Renee D Read; Paul J Goodfellow; Elaine R Mardis; Nancy Novak; Jon R Armstrong; Ross L Cagan
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

3.  Medullary thyroid carcinoma: a 25-year perspective.

Authors:  Xavier Matias-Guiu; Ronald De Lellis
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 4.  Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.

Authors:  Charlotte Lussey-Lepoutre; Alexandre Buffet; Aurélie Morin; Judith Goncalves; Judith Favier
Journal:  Cell Tissue Res       Date:  2018-02-09       Impact factor: 5.249

Review 5.  Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity.

Authors:  Patricia L M Dahia
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

Review 6.  Drosophila cancer models.

Authors:  Vivek A Rudrapatna; Ross L Cagan; Tirtha K Das
Journal:  Dev Dyn       Date:  2011-10-28       Impact factor: 3.780

7.  The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.

Authors:  William Grey; Rosaline Hulse; Anna Yakovleva; Dilyana Genkova; Benjamin Whitelaw; Ellen Solomon; Salvador J Diaz-Cano; Louise Izatt
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 8.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

Review 9.  Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma.

Authors:  Andreas Machens; Henning Dralle
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 10.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.